Business Description
Founded in 1993 and based in Ramat Gan, Israel, XTL Biopharmaceuticals focuses on finding and advancing treatments for autoimmune conditions. Its most advanced product, hCDR1, is prepared to enter Phase II clinical trials and targets diseases such as lupus and Sjogren's syndrome. The company holds a licensing agreement with Yeda Research and Development to support the ongoing study and future commercialization of hCDR1.
